Preview

Артериальная гипертензия

Расширенный поиск

Вазоактивные факторы в патогенезе преэклампсии

https://doi.org/10.18705/1607-419X-2006-12-1-22-31

Полный текст:

Аннотация

На сегодня ни одна проблема в акушерстве не вызывает столь пристального внимания как проблема преэклампсии и эклампсии. В общей популяции беременных женщин частота преэклампсии составляет 5-10 %, а эклампсии 0,05 %. В мировой литературе ежегодно публикуется более 1500 научных работ, посвященных различным аспектам этиологии, патогенеза, профилактики и лечения этого осложнения беременности, но многие вопросы так и остаются далекими от разрешения. На сегодняшний день нет единой теории этиологии и патогенеза преэклампсии, что в значительной степени затрудняет своевременную диагностику, оценку степени тяжести и проведение профилактических мероприятий. Данный обзор посвящен изучению роли эндогенных вазоактивных факторов в патогенезе гестационной гипертензии. Кроме того, детально рассмотрена роль эндогенных дигиталисоподобных ингибиторов Na/K-AТФазы (маринобуфагенин) в патогенезе преэклампсии.

Об авторе

В. А. Резник
Санкт-Петербургская Государственная Педиатрическая медицинская академия
Россия


Список литературы

1. MacKay A.P., Berg С.J., Afrash H.K. Pregnancy-related mortality from preeclampsia and eclampsia. Obstet. Gynecol. 2001; 97:533-538.

2. Saftlas A.F., Olson D.R., Franks A.L. et al. Epidemiology of preeclampsia and eclampsia in the United Stales. 1979-1986: Am. J. Obsiet Gynecol. 1990: 163: 460-465.

3. Various Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am. J Obstet. Gynecol. 2000: 183: S1-S21.

4. Crowther C.A. Eclampsia at Harare Maternity Hospital. An epidemiological study. South African Medical Journal, 1985; 68: 927-929.

5. Cunningham E.G., Lindheimer M.D. Hypertension in pregnancy, N. Engl. J. Med, 1992: 326: 927-932.

6. Department of Health. Report on Confidential Enquiries into Maternal Deaths in the UK. 1988-90. London: Doll., 1994: 22-33.

7. Douglas K.A., Redman C.W. Eclampsia in the United Kingdom. British Medical Journal 1994: 309: 1395-1400.

8. Mac Gillivray J. Some observations on lite Incidence of preeclampsia. J. Obstet Gynaecol. Br. Emp. 1958; 65: 536-539.

9. Eskenazi B., Fenster L., Sidney S. A multivariate analysis of risk factors for preeclampsia. JAMA. 1991; 266: 237-241.

10. Coonrod D.V., Hickok D.E., Zhu K. et al. Risk Jailors for preeclampsia in twin pregnancies: A population-based cohort study. Obsiet. Gynecol, 1995: 85: 645-650.

11. Li O.K., Wi S. Changing paternity and the risk of preeclampsia in the subsequent pregnancy. Am. J. Epidemiol. 2000; 151: 57-62.

12. Trupin L.S., Simon L.P., Eskenazi B. Change in paternity: A risk factor for preeclampsia in multiparas. Epidemiology. 1996; 7: 240-244.

13. Skjaerven R.S., Wilcox A.L., Lie R.T. The interval between pregnancies and the. risk of preeclampsia. N. Engl. J. Med. 2002: 346: 33-38.

14. Bootllard P.Y., Hulsey T.C., Periann J. et al. Association of pregnancу induced hypertension with duration of sexual to habitation before conception. Lancet 1994; 344: 973-975.

15. Van Back E., Peeters L.H. Pathogenesis of preeclampsia: A comprehensive model. Obstet. Gynecol. Sun. 1998: 53: 233-239.

16. Van Parnpus M.G., Dekker G.A., Wolf H. et al. High prevalence or hemostatic abnormalities in women «nth a history o/ severe preeclampsia. Am. J. Obstet. Gynecol. 1999: 180: 1146-1150.

17. Alsunyman O.M., Castro M.A., Zuckerman E. et al. Preeclampsia and liver infarction in early pregnancy associated with the antiphospholipid syndrome. Obstet. Gynecol. 1996; 88, 644-646.

18. Грацианский Н.А., Качалков Д.В., Давыдов С.А. Связь реакции коронарных артерий на внутрикоронарое введение ацетилхолина с факторами риска ишемической болезни сердца. Кардиология. 1999. 39. № 1. С. 25-30.

19. МсМаhoni P., Smith J. The HELLP syndrome at 16 weeks gestation: possible association with the antiphospholipid syndrome. Aust NZ. J. Obstet. Gynaecol. 1997; 37: 313-314.

20. Lockwood С.J. Inherited thrombophilias in pregnant patients: Detection and treatment paradigm. Obstet. Gynecol. 2002: 99: 333-341.

21. Dekker G.A., de Vries L.P., Doelutzsch P.M. et al. Underlying disorders associated with severe early-onset preeclampsia. Am. J Obstet. Gynecol. 1995; 173: 1042-1048.

22. Tyni T., Ekholdm E., Pihko H. Pregnancy complications are frequent In long-chain 3- hydroxylacyl coenzyme A dehydrogenase deficiency. Am. J. Obstet. Gynecol. 1998; 178: 603-608.

23. Ibdah J.A., Dasouki M.J., Strauss A.W. Long-chain 3-hydroxyacyl-CaF dehydrogenase deficiency. Variable expressivity of maternal illness during pregnancy and unusual presentation null infantile cholestasis and hypocalcaemia. J. Inhern. Metab. Dis. 1999; 2: 811-814.

24. Treem W.R., Rmaldo P., Hale D.E. et al. Acute fatty liver of pregnancy and long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency. Hepatology 1994; 19: 339-345.

25. Welzka P., Winkler К., Kuiner M. et al. Altered lipid metabolism in preeclampsia and HELLP syndrome: Links in enhanced platelet reactivity and fetal growth. Semin Thromb. Hemost 1999; 25: 455-462.

26. Репина M.A. Преэклампсия и материнская смертность, СПб.: Изд. Дом CIПбMAIIO. 2005.

27. Rippman E.Т. Organization gestosis. New approaches in terminology, prevention and therapy of gestosis. M., 1997. P. 18-19.

28. Айламазян Э.К. Неотложная помощь при экстремальных состояниях а в акушерской практике: Руководство. - М: Медицина. 1993.

29. Dekker G.A., Robillard Р.Y., Hulsey Т.С. Immune maladaption in the etiology of preeclampsia: A reviewoaf corroborative epidemiologic studies. Obstet. Gynecol. Sun 1998; 53: 377-382.

30. Graham С.H., Postovil H., Park M.T. et al. Hole of oxygen in the regulation of trophoblast gene expression and invasion. Placenta 2000; 21: 443-450.

31. Kovats В., Main E.K., Librach C. et al. A class I antigen. HLA-G, expressed in human trophoblast. Science 1990; 248: 220-223.

32. De Croot C.J., Bloemenkamp K.W., Duvekot E.J. et al. Preeclampsia and genetic risk factors for thrombosis: A case-control study. Am. J. Obstet. Gynecol., 1999; 181: 975-980.

33. Sihai B.M. Prevention of preeclampsia: A big disappointment. Am. J. Obstet Gynecol. 1998; 179: 1275-1278.

34. Lang R., Pridjian G., Feldman С. et al. Alterations in left ventricular mechanics in preeclampsia: Increased afterload or cardiomyopathy? Am. Heart. J. 1991; 121: 1768-1775.

35. Longo L.D. Maternal blood volume and cardiac output during pregnancy: A hypothesis of endocrinologic control Am. J Physiol. 1983; 245: R720-R729.

36. Lark S.L., Cotton D.B., Pivarnik J.M. et al. Position change mid central hemodynamic profile during norma third-trimester pregnancy and postpartum. Am. J. Obstet. Gynecol. 1991: 164: 883-887.

37. Podjarny E., Baylis C., Losonezy G. Animal models of preeclampsia. Semite Perinatal 1999; 23: 2-13.

38. Mabie W.C., Di Sessa T.G., Crocker L.G. et all. A longitudinal Study of cardiac output in normal human pregnancy. Am. J. Ohstet. Gynecol. 1994; 170: 849-856.

39. Baylis C., Engels K. Adverse interactions between pregnancy and a new model of systemic hypertension produced by chronic blockade of endothelial-derived relaxing factor (EDRF) in the rat. Clin. Exp. Hypertens. 1992; B11: 117-129.

40. Грибкова И.В., Шуберт Р., Серебряков В.И. NО активирует Са2+ активируемый К+ гладкомышечных клеток хвостовой артерии крысы через GMP — зависимый механизм // Кардиология. 2002. № 8. С. 34-37.

41. Зотова И.В., Затейщиков Д.A., Сидоренко Б.А. Синтез оксида азота и разввитие атеросклероза // Кардиология. № 4, 2003. C. 58-67.

42. Seligman S.P., Bayon J.P., Clancy P.M. et all. The role of nitric oxide in the pathogenesis of preeclampsia. Am. J. Obstet. Gynecol. 1994; 171: 944-948.

43. Khalil R.A., Crews J.K., Novak I et al. Enhanced vascular rem tint у during inhibition of nitric оxide synthesis in pregnant rats. Hypertension. 1998; 31: 1065-1069.

44. Molnar M., Suto T., Toth T. et all. Prolonged blockade of nitric oxide synthesis In gravid rats produces sustained hypertension, proteinuria, thrombocytopenia and intrauterine growth retardation. Am. J. Obstet. Gynecol. 1994; 170: 1458-1466.

45. Yallampalli C., Garfield P.P. Inhibition of nitric oxide synthesis in rats during pregnant у produces signs similar to those of preeclampsia. Am. J Obstet. Gynecol. 1993, 169: 1316-1320.

46. Walsh S.W. Preeclampsia: An imbalance in placenta! Prostacyclin and thromboxane production. Am. J. Obstet. Gynecol. 1985: 152: 335-340.

47. Wang Y., Walsh S.W., Kay H.H. Placental lipid peroxides and thromboxane me increased and prostacyclin is decreased in women with preeclampsia. Am. J Obstet Gynecol. 1992: 167: 946-949.

48. Wang Y., Walsh S.W., Guo J. et al. The imbalance between thromboxane and prostacyclin in preeclampsia is associated with an imbalance between lipid peroxides and vitamin E in maternal blood. Am. J. Obstet. Gynecol. 1991; 165: 1695-1700.

49. Kangawa K., Matsuo H. Purification and complete amino acid sequence of a-human atrial natriuretic peptide (a-hANP, 22). Biochem Biophys Res Commun 1984; 118: 131-139.

50. Campese V.M., Wederhom A. M.A. Natriuretic peptides. In: Oparil S., Weber M.A., eds. Hypertension: A Companion to Brenner and Rector's The Kidney. Philadelphia: WB Saunders. 2000. 164-176.

51. Wilkins M., Redondo J., Brown L. The natriuretic-peptide family. Lancet 1997; 349: 1307-1310.

52. De Bold A.J., Borenstein H.В., Veress A.T. et al. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. 1981: 28: 89-94.

53. Charles C.L., Espinosa P.A., Richards A.M. Cardiovascular actions of ANP: Contributions of renal, neurohumoral and hemodynamic factors in sheep Am. J. Physiol. 1993; 264: R533-538.

54. Wiedmann P., Hasler L., Gnadinger M.P. et all. Blood levels and renal effects of atrial natriuretic peptide in normal man. J. Clin. Invest. 1986; 77: 734-742.

55. Zafirovska K.G., Maleska V.T., Bogdanovska S.V. et all Plasma human atrial natriuretic peptide, endothelin-1, aldosterone and plasma-renin activity in pregnancy-induced hypertension. J. Hypertens 1999; 17: 1317-1322.

56. Kitamura К., Kangawа К., Каwamoto M. et al. Adrenumedullin a novel hypotensive peptide isolated from human pheochromocytoma. Biochem. Biophys. Pes. Commun. 1993: 192: 553-560.

57. Ishiyama Y., Kitamura К., Ichiki Y. et al. Hemodynamic effects of a novel hypotensive peptide, human adrenomedullin, in rats. Eur. J. Pharmacol. 1993; 241: 271-273.

58. Minegishi T., Nakamura M., Abe K. et all. Adrenomedullin and atrial natriuretic peptide content ml inns in normal pregnancy preeclampsia. Mol. Hum. Reprod. 1999: 5: 767-770.

59. Di Lorio R., Marinoni E., Letitzin С. et al. Adrenomedullin, a new vasoactive peptide, is increased in preeclampcia. Hypertension. 1998: 32: 758-763.

60. Clark B.A., Halverson L., Sachs B. et al. Plasma endothelin levels in preeclampsia. Evaluation and correlation with levels and renal impairment. Am. J Obstet. Gynecol. 1992; 166: 962-968.

61. Orbak Z., Zor N., Energin M. et al. Endothelin-1 levels in mothers with eclampsia -preeclampsia and their newborns. Trap. Pediatrr. 1998; 44: 17-19.

62. Kohan D.E. Endothelins in the normal and diseased kidney. Am. J Kidney Dis. 1997, 29: 2-26.

63. Shaarawy M., Abel-Mogid A-M.A. Plasma endolhelin-1 and mean arterial pressure in the prediction of preeclampsia. Seand. J. Clin. Lab. Invest. 1994: 53: 41-49.

64. Bussen S., Sitterlin M., Steek T. Plasma endothelin and big endothelin levels in women with severe preeclampsia at HELLP syndrome. Arch. Gynecol. Ohstet. 1999: 262: 113-119.

65. Dekker G.A., Kraaycnbriuk A.A. et al. Increased plasma levels of the novel vasoconstrictor peptide endothelin in severe preeclampsia. Eur. J. Obstet. Cyneco. Reprod. Biol., 1991: 40: 215-220.

66. Schiffrin P.L. Endothelin: potential role in hypertension and vascular hypertrophy. Hypertension 1995; 25: 1135-1143.

67. Singh H.L., Rahman A., Lirmie E.T. et all. Endothelin-1 in fetoplacental tissues from normotensive pregnant women and и women with preeclampsia. Acta. Obstet. Gynecol. Scand. 2001: 80: 99-103.

68. Taylor R.N., Varma M., Teng N.H. Et all. Women with preeclampsia have higher plasma endothelin levels than women with normal pregnancies. J. Clin. Endocrinol. Metab. 1990: 71: 675-1677.

69. Napolitano M., Miceli F., Calace A. et all. Expression and relationship between endothelin-1 messenger ribonucleic acid (mRNA) and inducible / endothelial nitric oxide synthase rnRNA isoforms from normal and preeclamptic placentas. J. Clin. Endocrinol. Metab. 2000; 85: 2318-2323.

70. Goodfrient T.L. Angiotensins actions and receptors. In Hypertension S. Oparil, M. Weber 2000, 11-13.

71. Weber M.A. Angiotensin II receptor blockers. In hypertensia S. Oparil, 2000, 377-378.

72. Weir M.R. Opportunities for cardiovascular risk reduction with angiotensin II receptor blockers. Current Hypertension Reports. 2002: 4: 333-335.

73. Моисеев С.В. Блокаторы ангиотензиновых или b-адренорецепторов при артериальной гипертонии. По материалам исследования LIFE. Клиническая фармакология и терапия. 2002. 11 (4): C. 58-62.

74. Charles C.L., Espinosa E.A., Richards A.M. Cardiovascular actions of ANF: Contributions of renal, neurohumoral and hemodynamic factors in sheep Am. J. Physiol. 1993: 264: R533-538.

75. Yundle T.G. Biochemistry of natriuretic peptides. J Intern. Med. 1994; 235: 561-576.

76. Kleinert H.O., Maack T., Atlas S.A. et all. Atrial natriuretic factor inhibits angiotensin, norepinephrine and potassium induced vascular contractility. Hypertension 1984; 6: 1-5.

77. Blaustein M. P. Physiological effects of endogenous ouabain control of intracellular Ca-2+ stores and cell responsiveness. Am. J. Physiol. 1994; 264, C. 1367-1387.

78. Bagrov A.Y., Fedorova O.V., Dmitrieva R.I., Howald W.N., Hunter A.P., Kuznetsova E.A., Shpen V.M. Characterization of a urinary bufodienolide Na+,K+ -ATPase inhibitor in patients after acute myocardial infarction. Hypertension. 1998; 31; 1097-103.

79. Fedorova O.V., Kolodkin N.L., Agalakova N.I., Lakatta E.G. Bagrov A.Y. Marinobufagenin and endogenous alpha-1 sodium pump ligand, in hypertensive. Dahl sah sensitive rats. Hypertension. 2001; 37: 462-466.

80. Periyasamy S.M., Liu J., Tanta F., Kabak В., Wakefield В., Malhotra P., Kennedy D.J., Nadoor A., Fedorova O.V., Gunning W., Xie Z. Bagrov A.Y., Shapiro J.L. Salt loading induces redistribution of the plasmalemmal Na/K-ATPase in proximal tubule cells. Kidney Int. 2005; 67: 1868-1877.

81. Fedorova O.V., Bagrov A.Y. Inhibition of Na/K ATPase from rat aorta by two endogenous Na/K pump inhibitors, ouabain and marinobufagenin. Evidence of interaction with different alpha-subinit isoforms. Am. J. Hypertens. 1997; 10: 929-935.

82. Gonick H.C., Ding Y., Vaziri N.D., Bagrov A.Y., Fedorova O.V. Simultaneous measurement of marinobufagenin. ouabain, and hypertension-associated protein in various disease states. Clin Exp Hypertens. 1998; 20: 617-627.

83. Fedorova O.V., Talan M.L., Agalakova N.L., Lakatta E.G., Bagrov A.Y. Endogenous ligand of alpha (l) sodium pump, marinobufagenin, is a novel mediator of sodium chloride-dependent hypertension. Circulation. 2002; 105: 1122-1127.

84. Лопатин Д.Л. Роль эндогенного дигоксиноподобного фактора маринобуфагенина, в патогенезе гестола. Дисс. … канд. мед. наук. Сиб. 2001.

85. Lopatin D.A., Ailamazian E.K., Dmitreeva R.I., Shpen V.M., Fedorova O.V., Doris P.A., Bagrov A.Y. Circulating bufodienolide and cardenolide sodium pump inhibitors in preeclampsia. J. Hypertension 17. 1999; 1179-1187.

86. Fedorova O.V., Kolodkin N.L., Agalakova N.L., Namikas A.R., Bzhelyansky A., St- Louis J., Lakatta E.G., Bagrov A.Y. Antibody to marinobufagenin lowers blood pressure in pregnant rats on a high NaCl intake. J Hypertens 2005; 23: 835-842.

87. Vu H.U., Lanosi-Irimie M.R., Pridjian C.A., Whitbred J.M., Durst J.M. Bagrov A.Y., Fedorova О.V., Pridjian P.G. Puschett J.В. The involvement of marinobufagenin in a rat model of human preeclampsia. Am J Nephrol 2005; 25: 520-528.

88. Goodlin R.C. Antigidoxin antibodies in eclampsia. New Engl J Med. 1988: 318: 518-519.

89. Adair C.D., Buckalew V., Taylor K., Ernest J.M., Frye A.M., Evans C., Veille J.С. Elevated endoxin-like factor complicating a middlefetal second trimester pregnancy: treatment with digoxin-binding immunoglobulin. Am J Nephrol 1996; 16: 529-531.

90. Adair D., Hinshaw A., Russell G., Rose J., Veille J., Buckalew V. Effects of Fab digoxin-specific antibodies on mean arterial pressure in severe preeclampsia. Am J Hypertens 1997; 10: 11A.


Для цитирования:


Резник В.А. Вазоактивные факторы в патогенезе преэклампсии. Артериальная гипертензия. 2006;12(1):22-31. https://doi.org/10.18705/1607-419X-2006-12-1-22-31

For citation:


Reznic V... Vasoactive factors in the preeclampsia pathogenesis. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2006;12(1):22-31. (In Russ.) https://doi.org/10.18705/1607-419X-2006-12-1-22-31

Просмотров: 107


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1607-419X (Print)
ISSN 2411-8524 (Online)